Sean P. Nolan

Sean is Chairman of the Board of Directors at Affinia Therapeutics. Previously, he served as Chief Executive Officer of gene therapy company AveXis until its acquisition by Novartis for $8.7 billion. Sean took the company through an IPO and built it into a fully integrated global organization with research, clinical, regulatory, manufacturing, and commercial capabilities. He was previously Chief Business Officer of InterMune, Chief Commercial Officer of Reata and Ovation Pharmaceuticals and President of Lundbeck’s U.S. affiliate. Sean serves on the Boards of Encoded Therapeutics, Itsari Oncology, Taysha and Ventas. He received his B.A. in Biology from John Carroll University.